Sebastian Mannweiler
Overview
Explore the profile of Sebastian Mannweiler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
817
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Downes M, Lajkosz K, Algaba F, Allory Y, Amin M, Cheng L, et al.
Histopathology
. 2025 Mar;
PMID: 40058790
Aims: A hybrid-three tier system with low grade (LG), high grade- G2 (HG-G2), high grade- G3 (HG-G3) has been proposed in recognition of, and to help address, the clinical heterogeneity...
2.
Moik F, Terbuch A, Sprakel A, Pichler G, Barth D, Pichler R, et al.
J Thromb Haemost
. 2025 Feb;
PMID: 39956429
Background: Patients with testicular germ cell tumors (TGCT) have a high cancer-specific survival rate. Objectives: We aimed to determine the short- and long-term risk of arterial thromboembolic events (ATE), their...
3.
Weiss J, Mannweiler S, Salminen H
Annu Rev Food Sci Technol
. 2025 Feb;
PMID: 39899844
Lipids are key compounds in foods and provide energy and nutrients to the body. They are carriers of aroma and flavor compounds and contribute to structure and texture. Nutritional research...
4.
Beijert I, Hentschel A, Brundl J, Comperat E, Plass K, Rodriguez O, et al.
Int Urol Nephrol
. 2023 Nov;
56(4):1323-1333.
PMID: 37980689
Purpose: A re-transurethral resection of the bladder (re-TURB) is a well-established approach in managing non-muscle invasive bladder cancer (NMIBC) for various reasons: repeat-TURB is recommended for a macroscopically incomplete initial...
5.
Egger V, Hutterer G, Mischinger J, Seles M, Pichler R, Mannweiler S, et al.
World J Urol
. 2023 Apr;
41(5):1359-1364.
PMID: 37024555
Purpose: Upper tract urothelial carcinoma (UTUC) represents an often aggressive malignancy associated with poor prognosis. Therefore, finding reliable prognostic biomarkers in patients undergoing curative surgery for improved risk stratification is...
6.
Sylvester R, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins H, et al.
Eur Urol
. 2023 Feb;
83(5):e140-e141.
PMID: 36841687
No abstract available.
7.
Beijert I, Hentschel A, Brundl J, Comperat E, Plass K, Rodriguez O, et al.
Eur Urol Oncol
. 2023 Jan;
6(2):214-221.
PMID: 36670042
Background: Ta grade 3 (G3) non-muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of an aggressive G3 component together with the...
8.
Fluhrer H, Hutterer G, Golbeck S, Stidl M, Niedrist T, Pichler R, et al.
Ther Adv Med Oncol
. 2022 Nov;
14:17588359221134065.
PMID: 36425872
Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has substantially advanced over the last three decades, whereby data from controlled clinical trials indicate significant improvements regarding patients' overall...
9.
Mischinger J, Schollnast H, Zurl H, Geyer M, Fischereder K, Adelsmayr G, et al.
Front Surg
. 2022 Oct;
9:1013389.
PMID: 36277287
Objective: Guidelines for previous negative biopsy (PNB) cohorts with a suspicion of prostate cancer (PCa) after positive multiparametric (mp) magnetic-resonance-imaging (MRI) often favour the fusion-guided targeted prostate-biopsy (TB) only approach...
10.
Beijert I, Hentschel A, Brundl J, Comperat E, Plass K, Rodriguez O, et al.
Eur Urol Focus
. 2022 May;
8(6):1627-1634.
PMID: 35577750
Background: The pathological existence and clinical consequence of stage T1 grade 1 (T1G1) bladder cancer are the subject of debate. Even though the diagnosis of T1G1 is controversial, several reports...